Evidence map›Paper›PMID 25150943›Full record

ArticleNeuropharmacology2014

Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: effect of antidepressant treatment.

Carolina Muguruza, Patricia Miranda-Azpiazu, Rebeca Díez-Alarcia, Benito Morentin, Javier González-Maeso, Luis F Callado, J Javier Meana

Open access · greenAbstract read
In one paragraph

Article in Neuropharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.

  1. Cortical 5-HTMolecular psychiatry · 2025
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Genetic modulation of thePNAS nexus · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Glucocorticoid receptor dysregulation underlies 5-HTThe Journal of biological chemistry · 2022
    Article
  12. Article
  13. Article
  14. Review
  15. Opposite alterations of 5-HTTranslational psychiatry · 2021
    Article
  16. Pivotal mental states.Journal of psychopharmacology (Oxford, England) · 2021
    Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Carolina MuguruzaDepartment of Pharmacology, University of the Basque Country UPV/EHU, and Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain.
Patricia Miranda-AzpiazuDepartment of Pharmacology, University of the Basque Country UPV/EHU, and Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain.
Rebeca Díez-AlarciaDepartment of Pharmacology, University of the Basque Country UPV/EHU, and Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain.
Benito MorentinSection of Forensic Pathology, Basque Institute of Legal Medicine, Bilbao, Spain.
Javier González-MaesoDepartments of Psychiatry, Neurology, and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Luis F CalladoDepartment of Pharmacology, University of the Basque Country UPV/EHU, and Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain; Biocruces Health Research Institute, Bizkaia, Spain. Electronic address: lf.callado@ehu.es.
J Javier MeanaDepartment of Pharmacology, University of the Basque Country UPV/EHU, and Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain; Biocruces Health Research Institute, Bizkaia, Spain.
University of the Basque Country · ESBioCruces Health research Institute · ESIcahn School of Medicine at Mount Sinai · US

Funding

Structure and function of the 5HT2A/mGluR2 complex in schizophreniaR01MH084894 · NIMH · VIRGINIA COMMONWEALTH UNIVERSITY · PI Javier Gonzalez-Maeso · 2009 to 2026
$6.8M
NIMH NIH HHS R01 MH084894
6 · The paper itself

Abstract

Several studies have demonstrated alterations in serotonin 5-HT2A (5-HT2AR) and glutamate metabotropic mGlu2 (mGlu2R) receptors in depression, but never in the same sample population. Recently it has been shown that both receptors form a functional receptor heterocomplex that is altered in schizophrenia. The present study evaluates the gene expression and protein density of 5-HT2AR and mGlu2/3R in the postmortem prefrontal cortex of subjects with major depressive disorder (n = 14) compared with control subjects (n = 14) in a paired design. No significant differences between subjects with depression and controls in the relative mRNA levels of the genes HTR2A, GRM2 and GRM3 were observed. The 5-HT2AR density evaluated by [(3)H]ketanserin binding was significantly lower in antidepressant-treated subjects (Bmax = 313 ± 17 fmol/mg protein; p < 0.05) compared to controls (Bmax = 360 ± 12 fmol/mg protein) but not in antidepressant-free subjects (Bmax = 394 ± 16 fmol/mg protein; p > 0.05). In rats, chronic treatment with citalopram (10 mg/kg/day) and mirtazapine (5 mg/kg/day) decreased mRNA expression and 5-HT2AR density whereas reboxetine (20 mg/kg/day) modified only mRNA expression. The mGlu2/3R density evaluated by [(3)H]LY341495 binding was not significantly different between depression and control subjects. The present results demonstrate no changes in expression and density of both 5-HT2AR and mGlu2/3R in the postmortem prefrontal cortex of subjects with major depressive disorder under basal conditions. However, antidepressant treatment induces a decrease in 5-HT2AR density. This finding suggests that 5-HT2AR down-regulation may be a mechanism for antidepressant effect.

Indexed as

Amino AcidsAnimalsAntidepressive AgentsCitalopramDown-RegulationFemaleHumansKetanserinMajor Depressive DisorderMaleMianserinMiddle AgedMirtazapineMorpholinesPrefrontal CortexRadioligand AssayAmino AcidsAntidepressive AgentsCitalopramKetanserinLY 341495metabotropic glutamate receptor 2metabotropic glutamate receptor 3MianserinMirtazapineMorpholinesReboxetineReceptor, Serotonin, 5-HT2AReceptors, Metabotropic GlutamateRNA, MessengerTritiumXanthenes5-HT(2A) receptorsAntidepressantsDepressionHuman brainmGlu(2/3) receptors

Identifiers

PMID25150943
PMCPMC12706166
OpenAlexW2024546964

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.